Table 1 Sociodemographic characteristics of the NMIBC patients
All patients (n = 1463) | BlaZIB | Urolife | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
High-risk (n = 922) | All (n = 541) | Low risk (n = 99) | Intermediate risk (n = 250) | High risk (n = 192) | ||||||||
n (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | N | (%) |
Patient characteristics | ||||||||||||
Age (years), mean (SD) | 70 | (10) | 72 | (10) | 66 | (9) | 65 | (10) | 66 | (9) | 67 | (7) |
Gender (% male) | 1187 | (81%) | 761 | (83%) | 426 | (79%) | 68 | (69%) | 196 | (78%) | 162 | (84%) |
Living situation | ||||||||||||
With partner | 1165 | (80%) | 707 | (77%) | 458 | (85%) | 79 | (80%) | 212 | (85%) | 167 | (87%) |
Without partner | 298 | (20%) | 215 | (23%) | 83 | (15%) | 20 | (20%) | 38 | (15%) | 25 | (13%) |
Employment | ||||||||||||
Paid job | 349 | (24%) | 171 | (19%) | 175 | (32%) | 31 | (31%) | 89 | (36%) | 55 | (29%) |
No paid job | 104 | (7%) | 49 | (5%) | 55 | (10%) | 13 | (13%) | 25 | (10%) | 17 | (9%) |
Retired | 1010 | (69%) | 699 | (76%) | 311 | (58%) | 55 | (56%) | 136 | (54%) | 120 | (62%) |
Comorbiditya | ||||||||||||
0 | 299 | (20%) | 212 | (23%) | 87 | (16%) | 12 | (12%) | 41 | (16%) | 34 | (18%) |
1 | 406 | (28%) | 270 | (29%) | 136 | (25%) | 27 | (27%) | 57 | (23%) | 52 | (27%) |
≥ 2 | 739 | (51%) | 425 | (46%) | 314 | (58%) | 59 | (60%) | 152 | (61%) | 103 | (54%) |
Missing | 15 | (1%) | 15 | (2%) | 0 | (0%) | 0 | (0%) | 0 | (0%) | 0 | (0%) |
Smoking status (at baseline) | ||||||||||||
Never | 225 | (15%) | 137 | (15%) | 88 | (16%) | 19 | (19%) | 40 | (16%) | 29 | (15%) |
Former | 983 | (67%) | 633 | (69%) | 350 | (65%) | 63 | (64%) | 155 | (62%) | 132 | (69%) |
Current | 252 | (17%) | 149 | (16%) | 103 | (19%) | 17 | (17%) | 55 | (22%) | 31 | (16%) |
Missing | 3 | (0%) | 3 | (0%) | 0 | (0%) | 0 | (0%) | 0 | (0%) | 0 | (0%) |
Tumour characteristics | ||||||||||||
Tumour stage | ||||||||||||
Ta | 403 | (28%) | 0 | (0%) | 403 | (75%) | 99 | (100%) | 250 | (100%) | 54 | (28%) |
T1 | 907 | (62%) | 786 | (85%) | 121 | (22%) | 0 | (0%) | 0 | (0%) | 121 | (63%) |
Tis | 153 | (10%) | 136 | (15%) | 17 | (3%) | 0 | (0%) | 0 | (0%) | 17 | (9%) |
Tumour grade | ||||||||||||
1 | 156 | (11%) | 24 | (3%) | 132 | (24%) | 99 | (100%) | 29 | (12%) | 4 | (2%) |
2 | 385 | (26%) | 125 | (14%) | 260 | (48%) | 0 | (0%) | 221 | (88%) | 39 | (22%) |
3 | 894 | (61%) | 747 | (81%) | 147 | (57%) | 0 | (0%) | 0 | (0%) | 147 | (77%) |
Missing | 28 | (2%) | 26 | (3%) | 2 | (0%) | 0 | (0%) | 0 | (0%) | 2 | (1%) |
Adjuvant intravesical therapy | ||||||||||||
None | 447 | (31%) | 176 | (19%) | 271 | (50%) | 91 | (92%) | 157 | (63%) | 23 | (12%) |
Chemotherapy | 146 | (10%) | 17 | (2%) | 129 | (24%) | 7 | (7%) | 82 | (33%) | 40 | (21%) |
BCG | 808 | (55%) | 690 | (75%) | 118 | (22%) | 1 | (1%) | 7 | (3%) | 110 | (57%) |
BCG + Chemotherapy | 62 | (4%) | 39 | (4%) | 23 | (4%) | 0 | (0%) | 4 | (2%) | 19 | (10%) |